Seroclearance of Hepatitis B surface antigen after entecavir treatment

被引：0
|
作者：
Halichidis, Stela [1 ]
Dumea, Elena [1 ]
Cambrea, Claudia S. [1 ]
机构：
[1] Clin Infect Dis Hosp, Constanta, Romania
来源：
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES | 2013年 / 22卷 / 02期
关键词：
TENOFOVIR DISOPROXIL FUMARATE; HBEAG-POSITIVE PATIENTS; ADEFOVIR DIPIVOXIL;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [21] A RISK PREDICTION MODEL FOR HEPATOCELLULAR CARCINOMA AFTER HEPATITIS B SURFACE ANTIGEN SEROCLEARANCE
    Yang, Hyun
    Jang, Jeong Won
    Bae, Si Hyun
    Nam, Heechul
    Lee, Hae Lim
    Lee, Sung Won
    Yoo, Sun Hong
    Song, Myeong Jun
    Kwon, Jung Hyun
    Lee, Ahlim
    Nam, Soon Woo
    Choi, Jong Young
    Yoon, Seung Kew
    HEPATOLOGY, 2022, 76 : S238 - S238
  • [22] ANTIVIRAL THERAPY AND RISK FOR HEPATOCELLULAR CARCINOMA AFTER HEPATITIS B SURFACE ANTIGEN SEROCLEARANCE
    Lee, Han Ah
    Kim, Seung Up
    Kim, Beom Kyung
    Ahn, Sang Hoon
    Lee, Hyun Woong
    Kim, Ja Kyung
    Sinn, Dong Hyun
    Seo, Yeon Seok
    HEPATOLOGY, 2023, 78 : S449 - S450
  • [23] EVIDENCE OF SEROLOGIC ACTIVITY IN CHRONIC HEPATITIS B AFTER SURFACE ANTIGEN (HBSAG) SEROCLEARANCE
    Seto, Wai-Kay
    Tanaka, Yasuhito
    Wong, Danny
    Lai, Ching-Lung
    Shinkai, Noboru
    Yuen, Chi Hang J.
    Tong, Teresa
    Fung, James
    Hung, Ivan F. N.
    Yuen, Man-Fung
    HEPATOLOGY, 2011, 54 : 1070A - 1070A
  • [24] Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance"
    Yip, Terry Cheuk-Fung
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    JOURNAL OF HEPATOLOGY, 2018, 68 (01) : 208 - 209
  • [25] Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B
    Lee, Hae Lim
    Jang, Jeong Won
    Han, Ji Won
    Lee, Sung Won
    Bae, Si Hyun
    Choi, Jong Young
    Han, Nam Ik
    Yoon, Seung Kew
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Min, Chang-Ki
    Kim, Dong-Wook
    Lee, Jong Wook
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (10) : 2992 - 3000
  • [26] Risk prediction model for hepatocellular carcinoma after hepatitis b e antigen seroclearance in patients treated with entecavir or tenofovir
    Lim, Tae Seop
    Jeon, Mi Young
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Kim, Seung Up
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E264 - E264
  • [27] The role of hepatitis B surface antigen quantification predict HBV reactivation after discontinuation of entecavir treatment
    Chen, Chien-Hung
    Lee, Chuan-Mo
    Hung, Chao-Hung
    Wang, JIng-Houng
    Lu, Sheng-Nan
    Hu, Tsung-Hui
    HEPATOLOGY, 2013, 58 : 655A - 655A
  • [28] Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
    Reijnders, Jurrien G. P.
    Rijckborst, Vincent
    Sonneveld, Milan J.
    Scherbeijn, Sandra M. J.
    Boucher, Charles A. B.
    Hansen, Bettina E.
    Janssen, Harry L. A.
    JOURNAL OF HEPATOLOGY, 2011, 54 (03) : 449 - 454
  • [29] Therapy of Hepatitis B: Is It Really Not Associated With Hepatitis B Surface Antigen Seroclearance? Reply
    Yeo, Yee Hui
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2019, 157 (01) : 267 - 268
  • [30] Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study
    Fung, James
    Seto, Wai-kay
    Wong, Danny Ka-ho
    Lai, Ching-lung
    Yuen, Man-fung
    LIVER INTERNATIONAL, 2015, 35 (03) : 854 - 859
12345